In_IN Vitro_NP and_CC In_IN Vivo_NP Antibacterial_JJ Activities_NNS of_IN DW286_NP ,_, a_DT New_NP Fluoronaphthyridone_NP Antibiotic_JJ The_NP in_IN vitro_NP and_CC in_IN vivo_JJ activities_NNS of_IN DW286_NP ,_, a_DT novel_JJ fluoronaphthyridone_NN with_IN potent_JJ antibacterial_NN activity_NN ,_, were_VBD compared_VBN with_IN those_DT of_IN ciprofloxacin_NP ,_, gemifloxacin_NP ,_, sparfloxacin_NN ,_, and_CC trovafloxacin_NN ._SENT Against_IN gram-positive_JJ bacteria_NNS ,_, such_JJ as_IN Staphylococcus_NP aureus_NN ,_, Staphylococcus_NP epidermidis_NP ,_, Streptococcus_NP pneumoniae_NNS ,_, and_CC Enterococcus_NP faecalis_NP ,_, the_DT in_IN vitro_NN activity_NN of_IN DW286_NP was_VBD stronger_JJR than_IN that_DT of_IN any_DT other_JJ reference_NN antibiotic_NN ._SENT Against_IN gram-negative_JJ bacteria_NNS ,_, the_DT activity_NN of_IN DW286_NP was_VBD similar_JJ to_TO those_DT of_IN trovafloxacin_NN and_CC gemifloxacin_NN but_CC was_VBD weaker_JJR than_IN that_IN of_IN ciprofloxacin_NN ._SENT In_IN a_DT mouse_NN systemic_JJ infection_NN caused_VBN by_IN three_CD S._NP aureus_NN strains_NNS ,_, including_VBG methicillin-resistant_JJ S._NP aureus_NN and_CC quinolone-resistant_JJ S._NP aureus_NN (_( QRSA_NP )_) ,_, DW286_NP demonstrated_VBD the_DT most_RBS potent_JJ activity_NN ,_, as_RB found_VBN in_IN vitro_NN ._SENT Specially_RB ,_, DW286_NP is_VBZ >=8-fold_NN more_RBR active_JJ against_IN QRSA_NP than_IN the_DT other_JJ fluoroquinolones_NNS ._SENT And_CC the_DT 50_CD %_NN protective_JJ doses_NNS for_IN DW286_NP were_VBD correspondent_NN with_IN the_DT in_IN vitro_NN activities_NNS ._SENT The_DT quinolones_NNS have_VBP evolved_VBN from_IN agents_NNS used_VBN solely_RB for_IN the_DT treatment_NN of_IN urinary_JJ tract_NN infections_NNS to_TO molecules_NNS with_IN potent_JJ activity_NN against_IN a_DT wide_JJ spectrum_NN of_IN significant_JJ bacterial_JJ pathogens_NNS ._SENT Progressive_JJ modifications_NNS in_IN their_PP$ molecular_JJ configurations_NNS have_VBP improved_VBN both_CC the_DT spectrum_NN and_CC potency_NN of_IN their_PP$ in_IN vitro_NN activities_NNS ._SENT These_DT compounds_NNS have_VBP been_VBN successfully_RB used_VBN in_IN clinics_NNS for_IN a_DT decade_NN ._SENT The_DT targets_NNS in_IN fluoroquinolone_JJ research_NN during_IN the_DT last_JJ few_JJ years_NNS include_VBP improving_VBG the_DT pharmacokinetic_JJ properties_NNS ,_, increasing_VBG the_DT activity_NN against_IN gram-positive_JJ cocci_NNS and_CC anaerobes_NNS and_CC against_IN fluoroquinolone-resistant_JJ strains_NNS ,_, and_CC improving_VBG activity_NN against_IN nonfermentative_JJ gram-negative_JJ species_NNS ._SENT In_IN addition_NN ,_, the_DT increasing_VBG pathogen_NN resistance_NN to_TO antimicrobial_JJ agents_NNS is_VBZ a_DT cause_NN of_IN concern_NN ._SENT This_DT increase_NN in_IN the_DT resistance_NN to_TO fluoroquinolone_NN emphasizes_VBZ the_DT importance_NN of_IN the_DT continued_JJ development_NN of_IN new_JJ structural_JJ candidates_NNS ._SENT The_DT use_NN of_IN newer_JJR fluoroquinolone_NN derivatives_NNS will_MD potentially_RB contribute_VB to_TO decreasing_VBG the_DT spread_NN of_IN resistance_NN to_TO other_JJ antimicrobial_JJ agents_NNS by_IN reducing_VBG the_DT selective_JJ pressure_NN on_IN other_JJ antibiotic_JJ groups_NNS ._SENT New_JJ candidates_NNS have_VBP been_VBN developed_VBN in_IN an_DT attempt_NN to_TO help_VB improve_VB this_DT situation_NN ._SENT DW286_NP ,_, 7-[3-(aminomethyl)-4-(methoxyimino)-3-methyltetrahydro-1H-1-pyrrolyl]-1-cyclopropyl-6-fluoro-4-oxo-1_JJ ,_, 4-dihydro[1,8]naphthyridine-3-carboxylic_JJ acid_JJ hydrochloric_JJ acid_NN salt_NN ,_, is_VBZ a_DT novel_JJ fluoronaphthyridoneantibacterial_JJ agent_NN that_WDT was_VBD synthesized_VBN for_IN this_DT purpose_NN ._SENT In_IN this_DT study_NN ,_, we_PP determined_VBD the_DT in_IN vitro_NN activity_NN of_IN DW286_NP in_IN several_JJ groups_NNS of_IN clinical_JJ isolates_NNS and_CC compared_VBN it_PP with_IN those_DT of_IN ciprofloxacin_NP ,_, gemifloxacin_NP ,_, sparfloxacin_NN ,_, and_CC trovafloxacin_NN ._SENT We_PP also_RB compared_VBD the_DT in_IN vivo_JJ protective_JJ efficacy_NN of_IN DW286_NP with_IN those_DT of_IN the_DT fluoroquinolones_NNS against_IN a_DT systemic_JJ infection_NN in_IN mice_NNS ._SENT The_DT studied_VBN compounds_NNS were_VBD obtained_VBN as_RB follows_VBZ :_: DW286_NP ,_, ciprofloxacin_NP ,_, sparfloxacin_NN ,_, and_CC gemifloxacin_NN were_VBD synthesized_VBN at_IN the_DT R_NP &_CC D_NP Center_NP ,_, Dong_NP Wha_NP Pharmaceutical_NP Company_NP ,_, Anyang_NP City_NP ,_, Korea_NP ._SENT Trovafloxacin_NP was_VBD provided_VBN by_IN Pfizer_NP Pharmaceuticals_NPS ,_, New_NP York_NP ,_, N.Y._NP Clinical_NP isolates_NNS were_VBD obtained_VBN from_IN hospitals_NNS in_IN Seoul_NP ,_, Korea_NP ,_, between_IN 1996_CD and_CC 2000_CD ._SENT The_DT challenge_NN organisms_NNS used_VBN in_IN the_DT mouse_NN systemic_JJ infections_NNS were_VBD as_RB follows_VBZ :_: Streptococcus_NN pyogenes_NNS ATCC_NP 8668_CD was_VBD obtained_VBN from_IN the_DT American_NP Type_NP Culture_NP Collection_NP (_( Rockville_NP ,_, Md._NP )_) ,_, and_CC Staphylococcus_NP aureus_NN Smith_NP was_VBD kindly_RB provided_VBN by_IN S._NP Goto_NP of_IN Toho_NP University_NP ,_, Tokyo_NP ,_, Japan_NP ._SENT Escherichia_NP coli_NNS MB4-01_NP ,_, Klebsiella_NP pneumoniae_NP MB4-02_NP ,_, Streptococcus_NP pneumoniae_NP MB4-21_NP ,_, Pseudomonas_NP aeruginosa_NP MB4-16_NP ,_, methicillin-resistant_JJ S._NP aureus_NN (_( MRSA_NP )_) MB4-19_NP ,_, and_CC quinolone-resistant_JJ S._NP aureus_NN (_( QRSA_NP )_) MB4-20_NP were_VBD selected_VBN through_IN the_DT pathogenicity_NN screening_NN of_IN clinical_JJ isolates_NNS ._SENT MICs_NNS were_VBD determined_VBN by_IN an_DT agar_NN dilution_NN method_NN with_IN Mueller-Hinton_NP agar_NN (_( Difco_NP Laboratories_NP ,_, Detroit_NP ,_, Mich._NP )_) following_VBG the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NPS procedure_NN ._SENT Haemophilus_NP influenzae_NP ,_, S._NP pyogenes_NNS ,_, and_CC S._NP pneumoniae_NNS were_VBD grown_VBN on_IN brain_NN heart_NN infusion_NN (_( Difco_NP )_) agar_NN supplemented_VBN with_IN 5_CD %_NN defibrinated_JJ sheep_NN blood_NN (_( Difco_NP )_) at_IN 37_CD C._NP The_NP in_IN vitro_NP antibacterial_NN activity_NN of_IN DW286_NP against_IN the_DT clinical_JJ isolates_NNS is_VBZ presented_VBN in_IN Table_NP ._SENT Its_PP$ antibacterial_NN activity_NN was_VBD superior_JJ to_TO those_DT of_IN ciprofloxacin_NP ,_, gemifloxacin_NP ,_, sparfloxacin_NN ,_, and_CC trovafloxacin_NN against_IN quinolone-sensitive_JJ S._NP aureus_NN (_( DW286_NP ,_, MIC_JJ at_IN which_WDT 50_CD %_NN of_IN the_DT isolates_NNS tested_VBN are_VBP inhibited_VBN [_SYM MIC50_NP ]_SYM =_SYM 0.008_CD mug/ml_NN ;_: MIC90_NP =_SYM 0.016_CD mug/ml_NN )_) and_CC QRSA_NP (_( DW286_NP ,_, MIC50_NP =_SYM 0.5_CD mug/ml_NN ;_: MIC90_NP =_SYM 8_CD mug/ml_NN )_) ._SENT DW286_NP was_VBD also_RB more_RBR active_JJ than_IN ciprofloxacin_NN and_CC sparfloxacin_NN and_CC was_VBD slightly_RB superior_JJ to_TO trovafloxacin_NN and_CC gemifloxacin_NN against_IN Staphylococcus_NP epidermidis_NP (_( DW286_NP ,_, MIC50_NP =_SYM 0.031_CD mug/ml_NN ;_: MIC90_NP =_SYM 0.25_CD mug/ml_NN )_) ,_, S._NP pyogenes_NNS (_( DW286_NP ,_, MIC50_NP =_SYM 0.016_CD mug/ml_NN ;_: MIC90_NP =_SYM 0.031_CD mug/ml_NN )_) ,_, and_CC Enterococcus_NP spp._NP (_( DW286_NP ,_, MIC50_NP =_SYM 1_CD to_TO 4_CD mug/ml_NN ;_: MIC90_NP =_SYM 4_CD to_TO 8_CD mug/ml_NN )_) ._SENT Its_PP$ antibacterial_NN activity_NN against_IN S._NP pneumoniae_NNS was_VBD fourfold_RB stronger_JJR than_IN those_DT of_IN gemifloxacin_NP and_CC trovafloxacin_NP (_( MIC90_NP =_SYM 0.125_CD mug/ml_NN for_IN DW286_NP and_CC 0.5_CD mug/ml_NN for_IN gemifloxacin_NN and_CC trovafloxacin_NN )_) ._SENT In_IN summary_NN ,_, DW286_NP exhibited_VBD potent_JJ in_IN vitro_NN antibacterial_NN activities_NNS against_IN gram-positive_JJ organisms_NNS ._SENT Specially_RB ,_, the_DT improved_VBN antibacterial_NN efficacy_NN of_IN DW286_NP against_IN pneumococci_NNS was_VBD the_DT most_RBS prominent_JJ difference_NN ._SENT Against_IN gram-negative_JJ bacteria_NNS ,_, including_VBG members_NNS of_IN the_DT family_NN Enterobacteriaceae_NP ,_, DW286_NP was_VBD less_RBR active_JJ than_IN ciprofloxacin_NN ,_, but_CC it_PP was_VBD as_RB active_JJ as_IN trovafloxacin_NN and_CC gemifloxacin_NN ._SENT The_DT MIC50_NP and_CC MIC90_NP for_IN clinical_JJ strains_NNS of_IN E._NP coli_NNS ,_, K._NP pneumoniae_NP ,_, Klebsiella_NP oxytoca_NP ,_, Enterobacter_NP cloacae_NNS ,_, Enterobacter_NP aerogenes_NNS ,_, and_CC Morganella_NP morganii_NP were_VBD 0.016_CD to_TO 0.25_CD mug/ml_NN and_CC 0.125_CD to_TO 0.5_CD mug/ml_NN ,_, respectively_RB ._SENT Its_PP$ activity_NN against_IN P._NP aeruginosa_NP (_( MIC50_NP =_SYM 4_CD mug/ml_NN ;_: MIC90_NP =_SYM 32_CD mug/ml_NN )_) was_VBD inferior_JJ to_TO that_DT of_IN ciprofloxacin_NP (_( MIC50_NP =_SYM 0.25_CD mug/ml_NN ;_: MIC90_NP =_SYM 2_CD mug/ml_NN )_) and_CC was_VBD slightly_RB inferior_JJ to_TO those_DT of_IN sparfloxacin_NP ,_, gemifloxacin_NN ,_, and_CC trovafloxacin_NN ._SENT Against_IN Serratia_NP marcescens_NP ,_, Xanthomonas_NP maltophilia_NP ,_, Acinetobacter_NP calcoaceticus_NP ,_, and_CC Proteus_NP spp._NP ,_, DW286_NP was_VBD less_RBR active_JJ than_IN the_DT other_JJ antibiotics_NNS ._SENT Its_PP$ activity_NN against_IN gram-negative_JJ organisms_NNS was_VBD comparable_JJ to_TO those_DT of_IN trovafloxacin_NN and_CC gemifloxacin_NN but_CC was_VBD less_JJR than_IN that_IN of_IN ciprofloxacin_NN ._SENT TABLE_NN 1_CD |_SYM In_IN vitro_NN antibacterial_NN activities_NNS of_IN DW286_NP and_CC quinolones_NNS against_IN clinical_JJ isolates_NNS The_DT effects_NNS of_IN serum_NN on_IN the_DT antibacterial_NN activity_NN of_IN DW286_NP against_IN S._NP aureus_NN ATCC_NP 25923_CD ,_, Bacillus_NN subtilis_NNS ATCC_NP 6633_CD ,_, and_CC E._NP coli_NNS ATCC_NP 25922_CD were_VBD also_RB evaluated_VBN ._SENT Heat-inactivated_JJ horse_NN serum_NN (_( Gibco_NP BRL_NP ,_, Gaithersburg_NP ,_, Md._NP )_) to_TO a_DT final_JJ concentration_NN of_IN 10_CD or_CC 25_CD %_NN (_( vol/vol_NN )_) had_VBD no_DT significant_JJ effect_NN on_IN the_DT activities_NNS of_IN DW286_NP and_CC the_DT other_JJ quinolones_NNS tested_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT protective_JJ efficacy_NN of_IN the_DT fluoroquinolones_NNS in_IN a_DT systemic_JJ infection_NN model_NN in_IN mice_NNS was_VBD determined_VBN ._SENT The_DT organisms_NNS used_VBN were_VBD S._NP aureus_NN Smith_NP ,_, S._NP pyogenes_NNS ATCC_NP 8668_CD ,_, E._NP coli_NNS MB4-01_NP ,_, K._NP pneumoniae_NP MB4-02_NP ,_, P._NP aeruginosa_NP MB4-16_NP ,_, S._NP pneumoniae_NP MB4-21_NP ,_, MRSA_NP MB4-19_NP ,_, and_CC QRSA_NP MB4-20_NP ._SENT The_DT organisms_NNS were_VBD cultured_VBN overnight_RB in_IN brain_NN heart_NN infusion_NN broth_NN at_IN 37C_JJ ._SENT Male_JJ ICR_NP mice_NNS (_( body_NN weight_NN ,_, 18_CD to_TO 22_CD g_NN ;_: age_NN ,_, 4_CD weeks_NNS )_) were_VBD inoculated_VBN intraperitoneally_RB with_IN 0.3_CD ml_NN of_IN a_DT bacterial_JJ suspension_NN adjusted_VBN with_IN 3_CD %_NN gastric_JJ mucin_NN (_( ICN_NP Biomedicals_NP ,_, Columbus_NP ,_, Ohio_NP )_) in_IN saline_JJ solution_NN at_IN 100_CD times_NNS the_DT minimal_JJ lethal_JJ dose_NN ._SENT The_DT challenge_NN inoculum_NN was_VBD sufficient_JJ to_TO kill_VB 100_CD %_NN of_IN the_DT untreated_JJ control_NN mice_NNS ,_, which_WDT died_VBD within_IN 48_CD h_NN postinfection_NN ._SENT Each_DT test_NN compound_NN was_VBD administered_VBN once_RB orally_RB to_TO mice_NNS immediately_RB after_IN infection_NN ._SENT Five_CD groups_NNS of_IN seven_CD mice_NNS each_DT were_VBD treated_VBN with_IN different_JJ doses_NNS of_IN each_DT antibacterial_NN agent_NN ._SENT The_DT 50_CD %_NN protective_JJ dose_NN (_( PD50_NP )_) was_VBD calculated_VBN by_IN the_DT method_NN of_IN Litchfield_NP and_CC Wilcoxon_NP from_IN the_DT survival_NN rates_NNS on_IN day_NN 7_CD after_IN infection_NN ._SENT The_DT protective_JJ effects_NNS of_IN DW286_NP against_IN systemic_JJ infections_NNS were_VBD compared_VBN with_IN those_DT of_IN ciprofloxacin_NP ,_, sparfloxacin_NP ,_, trovafloxacin_NN ,_, and_CC gemifloxacin_NN ._SENT In_IN this_DT mouse_NN infection_NN model_NN ,_, DW286_NP showed_VBD good_JJ in_IN vivo_JJ efficacies_NNS against_IN gram-positive_JJ organisms_NNS such_JJ as_IN S._NP aureus_NN ,_, including_VBG MRSA_NP and_CC QRSA_NP ,_, S._NP pyogenes_NNS ,_, and_CC S._NP pneumoniae_NNS ._SENT In_IN infections_NNS caused_VBN by_IN E._NP coli_NNS ,_, K._NP pneumoniae_NNS ,_, and_CC P._NP aeruginosa_NP ,_, its_PP$ activity_NN was_VBD inferior_JJ to_TO that_DT of_IN ciprofloxacin_NN ._SENT However_RB ,_, its_PP$ in_IN vivo_JJ efficacies_NNS were_VBD comparable_JJ to_TO those_DT of_IN trovafloxacin_NN and_CC gemifloxacin_NN ._SENT The_DT PD50s_NP for_IN DW286_NP correlated_VBD with_IN the_DT in_IN vitro_NP MICs_NP ._SENT Based_VBN on_IN its_PP$ in_IN vitro_NN activity_NN and_CC in_IN vivo_JJ efficacy_NN ,_, DW286_NP seems_VBZ to_TO be_VB a_DT promising_JJ antibiotic_NN with_IN a_DT broad_JJ spectrum_NN of_IN antimicrobial_JJ activity_NN ,_, including_VBG potent_JJ activity_NN against_IN S._NP aureus_NN and_CC S._NP pneumoniae_NNS ._SENT TABLE_NN 2_CD |_SYM Protective_JJ efficacy_NN of_IN DW286_NP on_IN systemic_JJ infections_NNS in_IN mice_NNS The_DT pharmacokinetic_JJ studies_NNS of_IN DW286_NP were_VBD performed_VBN after_IN oral_JJ administration_NN in_IN mice_NNS ,_, rats_NNS ,_, and_CC dogs_NNS (_( C._NP Lee_NP ,_, Y._NP Jung_NP ,_, J._NP Ryu_NP ,_, H._NP Kwon_NP ,_, and_CC J._NP Lee_NP ,_, Abstr_NP ._SENT 41st_NP Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NP ._SENT F-555_NP ,_, 2001_CD )_) ._SENT The_DT mean_JJ maximum_JJ concentrations_NNS (_( in_IN micrograms_NNS per_IN milliliter_NN )_) of_IN DW286_NP in_IN serum_NN in_IN mice_NNS were_VBD 1.06_CD ,_, 8.55_CD ,_, 24.28_CD ,_, and_CC 96.54_CD ,_, and_CC the_DT total_JJ areas_NNS under_IN the_DT concentration-time_JJ curve_NN (_( expressed_VBN in_IN micrograms_NNS hours/milliliter_NN )_) were_VBD 3.06_CD ,_, 30.56_CD ,_, 110.47_CD ,_, and_CC 783.90_CD at_IN each_DT dose_NN of_IN 10_CD ,_, 50_CD ,_, 250_CD ,_, and_CC 1,000_CD mg/kg_NN of_IN body_NN weight_NN ,_, respectively_RB ._SENT In_IN a_DT single_JJ oral_JJ administration_NN in_IN rats_NNS (_( 40_CD mg/kg_NN )_) and_CC dogs_NNS (_( 10_CD mg/kg_NN )_) ,_, the_DT maximum_JJ concentrations_NNS of_IN DW286_NP in_IN serum_NN were_VBD 9.06_CD mug/ml_NN (_( 2.0_CD h_NN )_) in_IN rats_NNS and_CC 3.95_CD mug/ml_NN (_( 3.33_CD h_NN )_) in_IN dogs_NNS ._SENT The_DT elimination_NN half-life_NN and_CC the_DT total_JJ area_NN under_IN the_DT concentration-time_JJ curve_NN were_VBD 4.5_CD h_NN and_CC 90.82_CD mug_NN h/ml_NN in_IN rats_NNS and_CC 5.37_CD h_NN and_CC 34.65_CD mug_NN h/ml_NN in_IN female_JJ dogs_NNS ._SENT Hence_RB ,_, the_DT pharmacokinetics_NN of_IN DW286_NP seem_VBP to_TO be_VB superior_JJ to_TO those_DT of_IN ciprofloxacin_NN ._SENT The_DT new_JJ fluoronaphthyridone_NN antibiotic_NN ,_, DW286_NP ,_, was_VBD absorbed_VBN efficiently_RB from_IN the_DT gastrointestinal_JJ tract_NN ,_, regardless_RB of_IN the_DT animal_JJ species_NN ._SENT The_DT pharmacokinetic_JJ data_NNS explain_VBP the_DT correlation_NN between_IN the_DT in_IN vitro_NN activity_NN and_CC the_DT in_IN vivo_JJ efficacy_NN ._SENT Our_PP$ findings_NNS need_VBP to_TO be_VB confirmed_VBN in_IN further_RBR preclinical_JJ and_CC clinical_JJ studies_NNS of_IN this_DT new_JJ fluoronaphthyridone_NN antibiotic_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Chemical_NP structure_NN of_IN DW286_NP ._SENT Chemical_JJ structure_NN of_IN DW286_NP ._SENT 